Q2 2025 Management View CEO Nello Mainolfi outlined major progress in 2025, declaring “the updates we've shared in the first ...

Q2 2025 Earnings Call Transcript August 11, 2025 Kymera Therapeutics, Inc. misses on earnings expectations. Reported EPS is $ ...

Kymera Therapeutics Inc (KYMR) extends cash runway into 2028, bolstered by key partnerships with Gilead and Sanofi, despite ...

Phase 1 healthy volunteer data surpassing Kymera’s target product profile, and further validating its oral, dupilumab-like profile KT-621 BroADen Phase 1b trial in moderate to severe atopic dermatitis ...

As for recent success stories from its biotech portfolio, Hatteras namechecked Kymera Therapeutics. The VC fund contributed ...

Detailed price information for Kymera Therapeutics Inc (KYMR-Q) from The Globe and Mail including charting and trades.

Kymera Therapeutics has introduced KT-579, a first-in-class oral degrader targeting IRF5, which may provide a transformative treatment option for various autoimmune diseases.

Kymera claims that targeted protein degradation may be a better solution. KT-621 is designed to grab STAT6 and drag it to the proteasome, the cell’s protein-shredder, for destruction.

Kymera Press, you see, is owned by Smith and all of the writers and artists are women. Kymera Press started with one title, a comic book based on a TV pilot that Smith wrote years before.

Have you had a look at all of the Kymera styles in Fortnite? Aliens have landed in Fortnite Chapter 2 Season 7, introducing the Kymera race of extraterrestrials to the battle royale game.